The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Avinasi Labs Enables a New Funding & Revenue Model for Clinical Stage Assets via DeLong Protocol SAN FRANCISCO, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — Avinasi Labs, an AI-native ...

Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board ...

Already FDA-cleared and in routine clinical use in Las Vegas, the Dynamis Robotic Surgical System is set for its next evolution, leveraging NVIDIA Jetson Thor, NVIDIA Isaac for Healthcare, and NVIDIA ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

An international research team identified hundreds of genes essential for the development of brain cells, including one gene ...

TARPON SPRINGS, Fla., December 31, 2025 - Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor ...

A UC San Diego lab recently announced a pair of scientific breakthroughs for Pitt-Hopkins and Rett syndromes that are slated ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...